| Autor: |
Micháliková D., Kaprinay B. Tyukos, Lipták B., Švík K., Slovák L., Sotníková R., Bezek Š., Gáspárová Z. |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
European Pharmaceutical Journal, Vol 65, Iss 2, Pp 12-16 (2018) |
| Druh dokumentu: |
article |
| ISSN: |
2453-6725 |
| DOI: |
10.2478/afpuc-2018-0008 |
| Popis: |
The aim of this study was to determine pharmacological possibilities of influencing the risk factors of metabolic syndrome (MetS). Hypertriacylglycerolemic (HTG) rats fed with high-fat-fructose diet (HFFD) were used as a model of the MetS. Wistar rats fed with standard diet were used as negative control group. HTG rats fed with HFFD for 8 weeks were used as positive control group. The effects of atorvastatin and SMe1EC2 were tested. The compounds were administered to the HTG rats after 5 weeks of HFFD, once a day for 3 weeks. After 8 weeks, the blood serum lipid profile and electrophysiology of neurotransmission in hippocampal sections were evaluated in vitro. SMe1EC2 and atorvastatin had a significant effect on total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-cholesterol) and atorvastatin had a significant effect on triacylglycerols (TGs). SMe1EC2 improved the long-term potentiation (LTP) course in the hippocampus. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
